Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
RE

REGN

Market Closed

Regeneron Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnology
US
15.41K employees
CEO: Leonard S. Schleifer
Founded: 1991
$951.43
+$0.00(+NaN%)
Market Cap
98.41B
Beta
0.24
52W Range
N/A
Dividend Yield
0.39%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Regeneron’s current price is 32.6% below its high-confidence PERT-weighted fair value, indicating potential undervaluation supported by strong DCF results. Financial health scores are excellent, reflecting robust liquidity and growth. However, Monte Carlo simulation reveals high volatility (107.72% CV) and 23.5% downside risk below the current price, signaling notable valuation variability.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore REGN

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

REGN in the Healthcare

Large Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →